Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Video Gaming and eSports ETF (ESPO) vs Mesoblast Limited (MESO) Price & Performance

VanEck Video Gaming and eSports ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

VanEck Video Gaming and eSports ETF vs Mesoblast Limited — how do they compare? VanEck Video Gaming and eSports ETF trades at $91.98, while Mesoblast Limited trades at $18.73 (market cap $2.31B). The key difference: Mesoblast Limited is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.

ESPOMESO
Sector
Sector/ThematicTechnology
52-Week High
$122.30$20.96
52-Week Low
$85.25$11.35
Market Cap
$2.31B
Enterprise Value
$2.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Video Gaming and eSports ETF

No Aura AI signal available yet.

Mesoblast Limited

Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.

Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Video Gaming and eSports ETF

ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.

Read more on ESPO

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO